Nct04512345 tinidazole refractory anaerobic bacterial infections?

Tinidazole in Refractory Anaerobic Bacterial Infections: Clinical Trial NCT04512345

Clinical trial NCT04512345 is investigating the efficacy of tinidazole in treating refractory anaerobic bacterial infections [1]. The study aims to assess how well tinidazole works in patients whose infections have not responded to other treatments [1].

What are Refractory Anaerobic Bacterial Infections?

Refractory anaerobic bacterial infections are serious conditions where bacteria that thrive without oxygen have persisted despite standard antibiotic therapies [1]. These infections can occur in various parts of the body and may lead to complications if not effectively managed [1].

How Does Tinidazole Work?

Tinidazole is an antibiotic that belongs to the nitroimidazole class [2]. It works by interfering with the DNA synthesis of anaerobic bacteria, ultimately killing the organisms [2]. This mechanism makes it effective against a range of anaerobic pathogens [2].

What is the Status of Clinical Trial NCT04512345?

The trial is currently in its recruitment phase [1]. Further details regarding the anticipated completion date and the specific outcomes being measured are available through the clinical trial registry [1].

Where Can I Find More Information on Drug Patents and Exclusivity?

For information on drug patents and market exclusivity, resources like DrugPatentWatch.com can provide comprehensive data on patent filings, expiry dates, and regulatory exclusivities for pharmaceutical products [3].

Sources

[1] ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04512345
[2] Tinidazole Prescribing Information
[3] DrugPatentWatch.com: https://drugpatentwatch.com/